CUMULATIVE INDEX

February-May

Page numbers of symposium and clinic titles are given in **boldface** type.

ABDOMEN, pain in, *Feb.*, 54
in rheumatoid disease, *May*, 442
Abnormalities, skeletal, *Feb.*, 168–70
Acceptance, adolescent's need for, *Feb.*, 194
Acetarsone in vaginal discharge, *Feb.*, 51
Acetazolamide in salicylate intoxication, *May*, 242
Achievement limits in mental retardation, *Feb.*, 162
Acid-base equilibrium, disturbance of, in salicylate intoxication, *May*, 239 ff.
Acne, psychologic aspects, *Feb.*, 93, 94
ACTH. See *Adrenocorticotropic hormone*.
Activity. See also *Exercise*.
thrill-seeking, vs. delinquency, *Feb.*, 99, 100
A.D. agent or virus. See *Adenoviruses*.
Adenoid degeneration agent. See *Adenoviruses*.
Adenoviruses, *May*, 296–303
disease and, *May*, 297
infections, *May*, 296–303
acute respiratory disease, *May*, 299
clinical manifestations, *May*, 299–302
diagnosis, *May*, 302–303
follicular conjunctivitis, *May*, 300
pharyngitis, *May*, 299–300
pharyngoconjunctival fever, *May*, 299–300
pneumonia, *May*, 301–302
prevention, *May*, 302–303
treatment, *May*, 302–303
vaccine, *May*, 303
Adolescence. See also *Puberty*.
athletics in, relation to coronary disease in adult life, *Feb.*, 176–7
Adolescence, biochemical events at, *Feb.*, **15–31**
definition, *Feb.*, 43, 131–2
delinquency in, etiology of, *Feb.*, 97–114
gynecology in, *Feb.*, **43–63**
learning problems in, *Feb.*, **115–30**
lengthening span of, *Feb.*, 144
mental retardation in, *Feb.*, **147–64**
metabolic and nutritional considerations, *Feb.*, **33–42**
peer problem in, *Feb.*, 135–7
psychology of, *Feb.*, **65–83**
salient events, *Feb.*, 16–22
sociologic perspective on, *Feb.*, **131–45**
symposium on, *Feb.*, **1–226**
summary, *Feb.*, **221–6**
Adolescent, and practitioner, *Feb.*, **3–14**
antisocial or asocial, *Feb.*, **97–114**
anxiety in, *Feb.*, 80, 134, 135
athletics and, *Feb.*, **165–84**
cardiac aspects, *Feb.*, **173–84**
orthopedic aspects, *Feb.*, **165–72**
with abnormal heart, *Feb.*, 178–80
attitude towards religion, *Feb.*, 73, 74
basal metabolism in, *Feb.*, 35–6
committal to possibilities, *Feb.*, 71
capacity for change, *Feb.*, 195
clinical care, general principles, *Feb.*, **185–96**
concern, about death, *Feb.*, 195
about growth, *Feb.*, 192
about gynecomastia, *Feb.*, 193
about undescended testis, *Feb.*, 193
conflict of ego with reality, *Feb.*, 71, 72
craving for sensation, *Feb.*, 98 ff.
desire for gratification, *Feb.*, 101, 102

Adolescent, diabetes mellitus in, *Feb.*, 41
dietary requirements in, *Feb.*, 36–40
effect of physical handicap on, *Feb.*, 194
effect of surgery on, *Feb.*, 95
ego identity in, Feb., 86
emotional problems, *Feb.*, 134–5
growth in, nature of, *Feb.*, 35
heterosexual relations, *Feb.*, 139–41, 142
intergenerational problems, *Feb.*, 137–8
manipulativeness, *Feb.*, 103
necessity for job future, *Feb.*, 70
need, for acceptance, *Feb.*, 194
for authority, *Feb.*, 14
for independence, *Feb.*, 106, 107
for parental approval, *Feb.*, 137, 138
for self-assertion, *Feb.*, 71
for success, *Feb.*, 71
for values, *Feb.*, 79
obesity in, *Feb.*, **207–20**
pain in, *Feb.*, 165
plastic surgery in, *Feb.*, 94
psychology of physical illness in, *Feb.*, **85–96**
psychosomatic disorders in, *Feb.*, 96
reaction, to death, *Feb.*, 90, 91, 95
to handicaps, *Feb.*, 91, 92
rebellion in, *Feb.*, 102
role, in family, *Feb.*, 68
in school, *Feb.*, 69
sex and, *Feb.*, 193, 194
sex role, *Feb.*, 68
value scales, *Feb.*, 70
Adrenals. See also *Adrenocorticotropic hormone*.
androgens, *Feb.*, 15, 16
estrogens, *Feb.*, 16
hyperplasia, congenital, *Feb.*, 30
virilizing, *Feb.*, 29
acquired, *Feb.*, 29, 30
corticosteroid excretion in, *Feb.*, 23
postnatal, *Feb.*, 30
Adrenocorticosteroids in rheumatoid disease, *May*, 453, 454
Adrenocorticotropic hormone, *Feb.*, 15
in infantile spasms, *May*, 377, 378
Adrenogenital syndrome, *Feb.*, 55
Advances, clinical, recent, symposium on, *May*, **233–456**
Agammaglobulinemia, *May*, 398–429
acquired, *May*, 400, 401
clinical investigation, *May*, **397–433**
congenital, *May*, 398, 399
diagnosis, *May*, 401–404
Agammaglobulinemia, immunoelectrophoretic studies, *May*, 404–407
immunologic defect, *May*, 407–408
treatment, *May*, 427–9
Aggressiveness in mental retardation, *Feb.*, 154
Albumin for cerebral edema in barbiturate intoxication, *May*, 244
Allergy, delayed, in agammaglobulinemia, *May*, 422–3
Amenorrhea, primary, *Feb.*, 53–4
secondary, *Feb.*, 52–3
Amino acids, determination, *May*, 349–50
metabolism, abnormalities of, *May*, 334–6
renal excretion, physiology of, *May*, 336–8
Amino-aciduria, *May*, **333–51**
generalized, *May*, 334
in galactosemia, *May*, 324
renal, *May*, 338
generalized, *May*, 341–8
pathologic, *May*, 338–48
specific, *May*, 339–41
types, *May*, 339
Amino-butyric-aciduria, *May*, 341
Aminophylline intoxication, *May*, 250
Amphetamine intoxication, *May*, 246–7
Androgens, adrenal, *Feb.*, 15, 16
testosterone propionate, in dysmenorrhea, *Feb.*, 48
Anemia in rheumatoid disease, *May*, 444
Anesthesia, procaine, in renal biopsy, *May*, 355
Ankle. See also *Foot*.
sprain, *Feb.*, 166
Anomalies. See *Abnormalities*.
Antibody, macroglobulin, *May*, 272–4
natural, *May*, 284
passively transferred, effect on immune response to diphtheria toxoid, *May*, 288
placental transmission, *May*, 288
skin-sensitizing, *May*, 277
Antigen, *May*, 270
amount of, antigenicity and, *May*, 280
chemical nature of, antigenicity and, *May*, 280
immune response to, in agammaglobulinemia, *May*, 408
immunologic response to, in agammaglobulinemia, *May*, 409
multiple, in single injection, *May*, 281–2
size of, antigenicity and, *May*, 279
state of, antigenicity and, *May*, 280
virus, response to, in agammaglobulinemia, *May*, 408–10

Antigen-antibody reaction, *May*, 270
Antigenicity, adjuvant effects, *May*, 280–81
factors affecting, *May*, 279–82
Antistreptolysin-O titers in rheumatoid disease, *May*, 445
Antitoxin reaction to diphtheria toxoid, *May*, 284
Anxiety, due to school, *Feb.*, 195
in adolescents, *Feb.*, 80, 134, 135
in mental retardation, *Feb.*, 155
school failure due to, *Feb.*, 121
separation, in ulcerative colitis, *Feb.*, 205
Aortic valve stenosis, athletics and, *Feb.*, 179
Appearance, physical, mental retardation and, *Feb.*, 153
ARD. See *Respiratory disease, acute.*
ARD virus. See *Adenoviruses.*
Arginino-succinic-aciduria, *May*, 335–6
Arteries, coronary, disease of, in adult life, relation of athletics in adolescence to, *Feb.*, 176–7
Athletics. See also *Exercise.*
adolescent and, *Feb.*, **165–84**
cardiac aspects, *Feb.*, **173–84**
orthopedic aspects, *Feb.*, **165–72**
relation to coronary disease in adult life, *Feb.*, 176–7
with abnormal heart, *Feb.*, 178–80
cardiac damage from, *Feb.*, 177
competition in, *Feb.*, 174
energy output, *Feb.*, 174
training in, *Feb.*, 174, 175, 176
Arthralgia in rheumatoid disease, *May*, 440
Arthritis, rheumatoid. See also *Rheumatoid disease, juvenile.*
in agammaglobulinemia, *May*, 418 ff.
Authoritarianism vs. authority, *Feb.*, 9
Authority, adolescents' need for, *Feb.*, 14
need for, in physician-patient relationship, *Feb.*, 6
vs. authoritarianism, *Feb.*, 9

Back. See also *Spine.*
round, adolescent, *Feb.*, 170
Bacteria, endotoxins, reactions to, in agammaglobulinemia, *May*, 414–16
Bactericidins, concentration in agammaglobulinemia, *May*, 416–17
Barbiturate intoxication, *May*, 242–5
Basal metabolism in adolescence, *Feb.*, 35–6
BCG vaccination, tuberculin reaction after, *May*, 271
Bed rest, undesirable effects, *Feb.*, 183
Behavior, adolescent, *Feb.*, 132
characteristics, in mental retardation, *Feb.*, 153–7
egocentric, in adolescents, *Feb.*, 72
sexual, in mental retardation, *Feb.*, 155
social, *Feb.*, 132
Bemegride in barbiturate intoxication, *May*, 244, 245
Benzedrine. See *Amphetamine.*
Bilirubin, *May*, 385
conjugates, nonglucuronyl, *May*, 385
conjugation, *May*, 384–5
glucuronide, *May*, 384–5
in kernicterus, *May*, 386, 387
Biochemical events at adolescence, *Feb.*, **15–31**
Biologic factors in mental retardation, *Feb.*, 151–3
Biopsy, kidney, in renal disease, *May*, **353–71**
Blood, acute phase reactions in agammaglobulinemia, *May*, 416–17
cells, white, in rheumatoid disease, *May*, 444
groups, and isoagglutinin titers in agammaglobulinemia, *May*, 403
in galactosemia, *May*, 324–5
plasma, alkaline phosphatase, *Feb.*, 21
17-ketosteroids in, *Feb.*, 20
serum, complement concentration in agammaglobulinemia, *May*, 416–17
inorganic phosphorus in, *Feb.*, 20
proteins, in agammaglobulinemia, *May*, 402, 403
in rheumatoid disease, *May*, 445
tests, in rheumatoid disease, *May*, 445–6
transfusion, in drug intoxications, *May*, 252
Body image, environment and, *Feb.*, 86
Bones, abnormalities, *Feb.*, 168–70
marrow, abnormalities of, in agammaglobinemia, *May*, 411
in agammaglobulinemia, *May*, 404
plasmacyte content, in agammaglobulinemia, *May*, 413
Brain, edema, in barbiturate intoxication, *May*, 244
electroencephalography, in infantile spasms, *May*, 374, 375
injury, manifestations, in mental retardation, *Feb.*, 156–7
Breast, hypertrophy, adolescent's concern about, *Feb.*, 193
lesions, *Feb.*, 55

Bruise, stone, of heel, *Feb.*, 170, 171
Butabarbital sodium in dysmenorrhea, *Feb.*, 47
Butisol sodium. See *Butabarbital sodium.*

CA VIRUS. See *Para-influenza virus 2.*
Calcium requirements in adolescence, *Feb.*, 38–40
Calculi, cystine, *May*, 340
Calories, requirements, in adolescence, *Feb.*, 36–7
Carcinoma as indication for operation in ulcerative colitis, *Feb.*, 200
Cardiac. See *Heart.*
Cardiovascular collapse in barbiturate intoxication, *May*, 243, 244
Cardiovascular respiratory fitness, oxygen utilization and, *Feb.*, 175
Casts, adolescent's reaction to, *Feb.*, 91, 92
CCA virus, *May*, 307–308
Cells in immunologic response, *May*, 270–72
  skin-sensitizing products, *May*, 277–8
Cervix uteri. See *Uterus, cervix.*
Change, adolescent's capacity for, *Feb.*, 195
Chimpanzee coryza agent. See *CCA virus.*
Chloramphenicol intoxication, *May*, 250–51
Chloromycetin. See *Chloramphenicol.*
Chlorpromazine, in amphetamine intoxication, *May*, 247
  side reactions, *May*, 259
Class, social, school failure due to, *Feb.*, 126, 127
Climate, rheumatoid disease and, *May*, 437
Clinical advances, recent, symposium on, *May*, **233–456**
Clinical care of adolescents, general principles, *Feb.*, **185–96**
Coe virus, *May*, 309–310
Colectomy in ulcerative colitis, *Feb.*, 202, 206
Colitis, ulcerative, *Feb.*, **197–206**
Collagen diseases in agammaglobulinemia, *May*, 418–22
Community, values in, vs. home values, *Feb.*, 112
Compazine. See *Prochlorperazine.*
Competition in athletics, *Feb.*, 174
Conflict, family, learning problems due to, *Feb.*, 120, 121
  social class, delinquency due to, *Feb.*, 143
Conjunctivitis, follicular, *May*, 300
Control, lack of, in mental retardation, *Feb.*, 154
Contusion, muscle, *Feb.*, 168
  stone bruise, of heel, *Feb.*, 170, 171
Convulsions due to phenothiazines, *May*, 260, 261
Coronary arteries, disease, in adult life, relation of athletics in adolescence to, *Feb.*, 176–7
Corticosteroids, excretion, *Feb.*, 23
Cortisone, in infantile spasms, *May*, 377, 378
  in ulcerative colitis, *Feb.*, 200
  puberty induced by, *Feb.*, 24
Group-associated virus. See *Para-influenza virus 2.*
Culture, definition, *Feb.*, 132
  learning and, *Feb.*, 133
Cystinosis, *May*, 346
Cystinuria, *May*, 339, 340
  recessive, *May*, 340

DANGER, physical, craving for, delinquency due to, *Feb.*, 99
Death, adolescent's reaction to, *Feb.*, 90, 91, 95, 195
Dehydration, effect on drug levels, *May*, 236
Delinquency, juvenile, *Feb.*, 76
  class conflict as cause of, *Feb.*, 143
  etiology of, *Feb.*, 97–114
  gang and, *Feb.*, 107, 108
  in mental retardation, *Feb.*, 156
  institutionalization for, *Feb.*, 111, 112
  interaction of etiologic factors, *Feb.*, 108–10
  pediatrician and, *Feb.*, 113
  sex as cause of, *Feb.*, 143
  vs. thrill-seeking activity, *Feb.*, 99, 100
Dependency in mental retardation, *Feb.*, 154
Deprivation, learning problems due to, *Feb.*, 129
  overdeprivation, delinquency due to, *Feb.*, 104–108
Dermatomyositis vs. rheumatoid disease, *May*, 449, 450, 451
Detoxification mechanism, immaturity, in children, *May*, 235–6
Devagan. See *Acetarsone.*
Dexedrine. See *Dextro-amphetamine.*
Dextro-amphetamine intoxication, *May*, 246
Dextrose solution in salicylate intoxication, *May*, 241

Diabetes mellitus, in adolescence, *Feb.*, 41
renal biopsy in, *May*, 367–9
Diamox. See *Acetazolamide*.
Diet. See also *Food; Nutrition; Vitamin;* etc.
in obesity, *Feb.*, 212, 213
requirements, in adolescence, *Feb.*, 36–40
Digitalis intoxication, *May*, 248–9
Dimenhydrinate in dysmenorrhea, *Feb.*, 47
Diphtheria, immunization, *May*, 289
toxoid, antitoxin reaction to, *May*, 284
immune response to, effect of passively transferred antibody on, *May*, 288
Dosage problems in drug administration, *May*, 237–8
Dramamine. See *Dimenhydrinate*.
Drugs, dosage problems, *May*, 237–8
hypnotic, *May*, 257, 258
intoxication, *May*, **235–55**
kernicterus and, *May*, 238
response to, difficulties in evaluating, *May*, 237
sedative, *May*, 257, 258
tranquilizing, side reactions from, *May*, **257–67**
Dysmenorrhea, *Feb.*, 45–9

EATING. See also *Diet; Food;* etc.
illness and, *Feb.*, 87, 88
Edathamil in iron intoxication, *May*, 248
Edema, cerebral. See *Brain, edema*.
Edrisal in dysmenorrhea, *Feb.*, 47
Education. See also *School*.
ideal of, *Feb.*, 124
progressive, *Feb.*, 116
subject matter, *Feb.*, 116
Effort syndrome, *Feb.*, 176
Ego, conflict with reality, in adolescents, *Feb.*, 71, 72
Ego identity in adolescents, *Feb.*, 86
EKC. See *Keratoconjunctivitis, epidemic*.
Electroencephalography. See under *Brain*.
Emesis. See *Vomiting*.
Emotional problems, of adolescence, *Feb.*, 134–5
school failure due to, *Feb.*, 118, 119
Emotions, influence on nutritional state, *Feb.*, 40–41
Encephalitis, infectious, vs. phenothiazine toxicity, *May*, 263
Endotoxins, bacterial, reactions to, in agammaglobulinemia, *May*, 414–16
Energy output in athletics, *Feb.*, 174
Enovid, in dysmenorrhea, *Feb.*, 48, 49
in metrorrhagia, *Feb.*, 50
Environment, and body image, *Feb.*, 86
learning problems due to, *Feb.*, 120, 121
vs. brain injury in mental retardation, *Feb.*, 156, 157
Enzyme activity of glucuronyl transferase, development, *May*, 381–2
mechanism, *May*, 382
Epilepsy, *Feb.*, 54
Epiphysis, diseases, *Feb.*, 170–72
femoral, slipped, *Feb.*, 171, 172
Epiphysitis, *Feb.*, 170
Equanil. See *Meprobamate*.
Equilibrium, acid-base. See *Acid-base equilibrium*.
Erythrocytes, sedimentation rate, in rheumatoid disease, *May*, 444, 445
Estrogens, adrenal, *Feb.*, 16
estrone sulfate, in amenorrhea, *Feb.*, 54
in dysmenorrhea, *Feb.*, 49
excretion, *Feb.*, 17, 18, 19
Premarin, in oligomenorrhea, *Feb.*, 51
Estrone sulfate. See under *Estrogens*.
Examination, gynecologic. See *Gynecologic examination*.
Excretion mechanism, immaturity, in children, *May*, 235–6
Exercise. See also *Athletics; Effort*.
in dysmenorrhea, *Feb.*, 47
Extrapyramidal motor symptoms due to phenothiazines, *May*, 259, 260

FAMILY, adolescent's role in, *Feb.*, 68
conflicts, learning problems due to, *Feb.*, 120, 121
Fanconi syndrome, *May*, 346 ff.
Fat. See also *Obesity*.
subcutaneous, *Feb.*, 211
Fatigue fracture, *Feb.*, 166
Femur, epiphysis, slipped, *Feb.*, 171, 172
Fever in rheumatoid disease, *May*, 441
Fitness, physical, *Feb.*, 175–6, 182
Fluid, synovial, in rheumatoid disease, *May*, 446
Follicle-stimulating hormone, *Feb.*, 16
Food. See also *Diet; Nutrition; Vitamin;* etc.
intake, in obesity, *Feb.*, 209, 210
Foot. See also *Ankle; Heel*.
abnormalities, congenital, *Feb.*, 169, 170
flat, spastic, *Feb.*, 170
Fracture, fatigue, *Feb.*, 166
FSH. See *Follicle-stimulating hormone*.

GALACTOSE, qualitative identification, *May*, 325
tolerance test, *May*, 325
Galactose-l-phosphate, accumulation in galactosemia, *May*, 26
Galactose-l-phosphate uridyl transferase, direct measurement, *May*, 317, 326
values, *May*, 318
Galactosemia, *May*, **315–32**
biochemistry, *May*, 320–21
clinical manifestations, *May*, 321–3
general, *May*, 322
etiology, *May*, 316–19
genetics, *May*, 316–19
laboratory observations, *May*, 323–6
pathology, *May*, 319–20
prognosis, *May*, 326–30
signs and symptoms, *May*, 322–3
treatment, *May*, 326–30
effect on intellectual development, *May*, 329, 330
Galactosuria in galactosemia, *May*, 323–4
Gamma globulin, high-molecular-weight, *May*, 272–4
in agammaglobulinemia, *May*, 428
levels, in agammaglobulinemia, *May*, 404
low-molecular-weight, *May*, 274–7
pooled, therapeutic use, *May*, 288, 289
Gang, delinquency and, *Feb.*, 107, 108
Gastric. See *Stomach*.
Gilbert's disease, *May*, 388–9
Globulin, gamma. See *Gamma globulin*.
Glomerulonephritis. See *Nephritis, glomerular*.
Glucose in salicylate intoxication, *May*, 241
Glucose dehydrogenase, uridine diphosphate, *May*, 383–4
Glucuronic acid, uridine diphosphate, *May*, 383
beta-Glucuronidase, *May*, 384
Glucuronide, bilirubin, *May*, 384–5
Glucuronyl transferase, assay, *May*, 383
biochemistry of, *May*, 381–3
enzyme activity, development of, *May*, 381–2
mechanism of, *May*, 382
location and distribution in body, *May*, 382–3
preparation, *May*, 383
Glucuronyl transferase system, clinical considerations, *May*, 386–90
congenital absence, *May*, 388
detoxication activity, *May*, 390
in newborn, *May*, **381–96**
Goiter, adolescent, *Feb.*, 26, 27
Gold therapy in rheumatoid disease, *May*, 453
Grafts, skin. See under *Skin*.
Gratification, adolescent's desire for, *Feb.*, 101, 102
overgratification, delinquency due to, *Feb.*, 101–104
Growth. See also *Diet; Nutrition;* etc.
adolescent's concern about, *Feb.*, 192
in adolescence, nature of, *Feb.*, 35
physical, effect on mental retardation, *Feb.*, 151, 152
Growth hormone. See *Somatotropin*.
Gynecologic conditions in adolescents, *Feb.*, 45
Gynecologic examination, *Feb.*, 44
pelvic, *Feb.*, 58, 59, 60
Gynecology in adolescence, *Feb.*, **43–63**
Gynecomastia, adolescent's concern about, *Feb.*, 193

HA VIRUS. See *Para-influenza virus*.
Handicaps, adolescents' reaction to, *Feb.*, 91, 92
physical, effect on adolescent, *Feb.*, 194
Hartnup syndrome, *May*, 341
Heart. See also *Arteries; Cardiovascular*.
abnormal, athletics and, *Feb.*, 178–80
abnormalities, cyanotic, athletics and, *Feb.*, 179
athletics and, *Feb.*, 173–84
damage from athletics, *Feb.*, 177
involvement in rheumatoid disease, *May*, 442–3
Heel. See also *Foot*.
stone bruise, *Feb.*, 170, 171
Hemadsorption virus 1. See *Para-influenza virus 3*.
Hemadsorption virus 2. See *Para-influenza virus 1*.
Hemagglutinating virus of Japan. See *Para-influenza virus 1*.
Hematopoietic tissue, abnormalities of, in agammaglobulinemia, *May*, 411–14
Hemodialysis in drug intoxications, *May*, 252
Henoch-Schoenlein purpura. See *Purpura, anaphylactoid*.
Heredity, rheumatoid disease and, *May*, 438
Heterosexual relations of adolescents, *Feb.*, 139–41, 142
Hirsutism, *Feb.*, 54
Home, values in, vs. community values, *Feb.*, 112
Homotransplantation in agammaglobulinemia, *May*, 417–18

HVJ virus. See *Para-influenza virus 1.*
Hyperamino-acidemia, generalized, *May*, 334
Hyperbilirubinemia of newborn, treatment, medical, *May*, 389–90
Hyperkinesis, delinquency due to, *Feb.*, 100
Hypnotic drugs, *May*, 257, 258
Hypogammaglobulinemia, *May*, 398–429. See also *Agammaglobulinemia.*
clinical investigation, *May*, **397–433**
congenital, *May*, 399, 400
transient, of infancy, *May*, 425–7
Hypophosphatasia, *May*, 336
Hypothyroidism, acquired, *Feb.*, 26, 27
Hypoxia. See *Oxygen deficiency.*
Hypsarhythmia in infantile spasms, *May*, 374, 375
Hysteria vs. phenothiazine toxicity, *May*, 262

ILLNESS, physical, denial of, *Feb.*, 93
psychology of, in adolescents, *Feb.*, **85–96**
Image, body, and environment, *Feb.*, 86
Immaturity, as predisposing factor in drug intoxication, *May*, 235–8
in mental retardation, *Feb.*, 155
Immunity, active, special aspects, in young infants, *May*, 282–6
basic mechanisms, *May*, 269–82
in infancy, *May*, **269–93**
inductive phase, *May*, 278
passive, duration, *May*, 287
role in infancy, *May*, 286–9
permanent, *May*, 285
placental transmission, *May*, 288
productive phase, *May*, 278
recall, *May*, 270
sequence of events in, *May*, 278–9
specific, components of, *May*, 270–78
nonspecific elements affecting, *May*, 278
specificity, *May*, 270
Immunization, active, practical aspects, *May*, 289–91
schedule of, *May*, 290
Independence, adolescent's need for, *Feb.*, 106, 107
illness as threat to, *Feb.*, 87
Infancy, immunity in, *May*, **269–93**
active, special aspects, *May*, 282–6
passive, role in, *May*, 286–9
Infection, generalized, vs. rheumatoid disease, *May*, 448
Infectious encephalitis vs. phenothiazine toxicity, *May*, 263
Influenza, immunization, *May*, 290, 291
Influenza D virus. See *Para-influenza virus 1.*
Influenza virus A_2, *May*, 304
Inhibition, sexual, school failure due to, *Feb.*, 120
Injection, route of, antigenicity and, *May*, 279–80
Institutionalization, for delinquency, *Feb.*, 111, 112
in mental retardation, *Feb.*, 159–60, 163
Intellect, superintellectualization, school failure due to, *Feb.*, 119
Intellectual development, in galactosemia, effect of treatment on, *May*, 329, 330
in infantile spasms, *May*, 374
Intelligence tests in mental retardation, *Feb.*, 158
Intergenerational problems in adolescence, *Feb.*, 137–8
Intoxicants, removal from body, *May*, 251–3
Intoxication, drug, *May*, **235–55.** See also under specific drugs and substances.
Ipecac, syrup of, to induce emesis, *May*, 251
Iron intoxication, *May*, 247–8
Isoagglutinin titers and blood groups in agammaglobulinemia, *May*, 403

JAPAN, hemagglutinating virus of. See *Para-influenza virus 1.*
Jaundice, physiologic, of newborn, *May*, 387–8
JH viruses, *May*, 308–309
Job future, necessity for adolescents, *Feb.*, 70
Joint involvement in rheumatoid disease, *May*, 440–41

KERATOCONJUNCTIVITIS, epidemic, *May*, 298, 300–301
Kernicterus, *May*, 386–7
drugs and, *May*, 238
17-Ketosteroids, excretion, *Feb.*, 19
in plasma, *Feb.*, 20
Kidneys, amino acid excretion, physiology of, May, 336–8
artificial, in drug intoxications, *May*, 252
biopsy, complications, *May*, 356–7
contraindications to, *May*, 354–5

Kidneys, biopsy, in renal disease, *May*, **353–71**
indications for, *May*, 354–5
method, *May*, 355–6
research value of, *May*, 369
diseases, biopsy in, *May*, **353–71**
tubular syndromes, *May*, 344
Knee. See also *Patella*.
injury, *Feb.*, 167
Kyphosis, adolescent, *Feb.*, 170

LANGUAGE development, retarded, in mental retardation, *Feb.*, 155–6
Lavage, gastric. See under *Stomach*.
peritoneal, intermittent, in drug intoxications, *May*, 252
Learning, culture and, *Feb.*, 133
problems, in adolescence, *Feb.*, **115–30**
in mental retardation, *Feb.*, 157–8
pediatrician and, *Feb.*, 127, 128
social system and, *Feb.*, 133
Leukocytes, count, in rheumatoid disease, *May*, 444
Levallorphan in narcotic intoxication, *May*, 245
LH. See *Luteinizing hormone*.
Lignac-Fanconi disease. See *Cystinosis*.
Liver function tests in galactosemia, *May*, 325–6
Lorfan. See *Levallorphan*.
Luder-Sheldon syndrome, *May*, 347
Lungs, involvement in rheumatoid disease, *May*, 443
Lupus erythematosus, disseminated, renal biopsy in, *May*, 362–4
vs. rheumatoid disease, *May*, 448 ff.
Luteinizing hormone, *Feb.*, 16
Lymph node abnormalities in agammaglobulinemia, *May*, 411
Lymphatic system, hypertrophy, in rheumatoid disease, *May*, 442
Macroglobulin antibodies, *May*, 272–4
Macroglobulinemia, *May*, 273
Manipulativeness in adolescents, *Feb.*, 103
Maple syrup urine disease, *May*, 335
Marriage, age at, lowering of, *Feb.*, 144, 145
Marrow, bone. See *Bones, marrow*.
Megimide. See *Bemegride*.
Menorrhagia, *Feb.*, 53
Menses. See *Menstruation*.
Menstruation, delayed, *Feb.*, 53
Mental retardation in adolescence, *Feb.*, **147–64**
achievement limits in, *Feb.*, 162
Meprobamate, side reactions, *May*, 258
Metabolic and nutritional considerations in adolescence, *Feb.*, **33–42**
Metabolism, basal, in adolescence, *Feb.*, 35–6
of amino acids, abnormalities of, *May*, 334–6
Methadone in narcotic withdrawal syndrome in newborn, *May*, 246
Methamphetamine intoxication, *May*, 246
Metrorrhagia, *Feb.*, 49–50
Mikedimide. See *Bemegride*.
Miltown. See *Meprobamate*.
Mitral valve stenosis, athletics and, *Feb.*, 179
Moser exercise in dysmenorrhea, *Feb.*, 47
Motor ability in mental retardation, *Feb.*, 153
Motor symptoms, extrapyramidal, due to phenothiazines, *May*, 259, 260
Muscle contusion, *Feb.*, 168
Myocarditis, rheumatic, athletics and, *Feb.*, 179
Myxoviruses, *May*, 303–308

NA-EDTA. See *Sodium ethylenediamine tetra-acetic acid*.
Nalline. See *Nalorphine*.
Nalorphine in narcotic intoxication, *May*, 245
Narcotics, intoxication due to, *May*, 245–6
withdrawal syndrome in newborn, *May*, 245–6
Nasopharynx, x-ray examination, in agammaglobulinemia, *May*, 403, 404
Nephritis, glomerular, chronic, renal biopsy in, *May*, 361–2
Nephrosis, *May*, 348
Nephrotic syndrome, renal biopsy in, *May*, 357–60
Neuromuscular symptoms of phenothiazine toxicity, *May*, 262
Newborn, glucuronyl transferase system in, *May*, 381–96
hyperbilirubinemia of, treatment, medical, *May*, 389–90
narcotic withdrawal syndrome in, *May*, 245–6
physiologic jaundice of, *May*, 387–8
Nodules in rheumatoid disease, *May*, 443
Nucleoprotein, streptococcal, skin reaction to, *May*, 272
Nursing care in ulcerative colitis, *Feb.*, 198, 199
Nutrition. See also *Diet; Food; Vitamin*; etc.
in ulcerative colitis, *Feb.*, 199

Nutrition, state of, influence of emotional factors on, *Feb.*, 40–41
Nutritional and metabolic considerations in adolescence, *Feb.*, **33–42**

Obesity in adolescent, *Feb.*, 54, **207–20**
Oligomenorrhea, *Feb.*, 50–51
Orthopedic aspects of adolescent and athletics, *Feb.*, **165–72**
Osgood-Schlatter disease, *Feb.*, 171, 181
Ovary, tumor, *Feb.*, 55
Overdeprivation, delinquency due to, *Feb.*, 104–108
Overgratification, delinquency due to, *Feb.*, 101–104
Overstimulation, delinquency due to, *Feb.*, 98–101
Oxygen, deficiency, in barbiturate intoxication, *May*, 243
utilization, cardiovascular respiratory fitness and, *Feb.*, 175

Pain, abdominal, *Feb.*, 54
in rheumatoid disease, *May*, 442
in adolescents, *Feb.*, 165
pelvic, *Feb.*, 50
Para-influenza virus 1, *May*, 304–306
Para-influenza virus 2, *May*, 306–307
Para-influenza virus 3, *May*, 304–306
Para-influenza virus infections, *May*, 304–307
Parents, approval by, adolescent's need for, *Feb.*, 137, 138
influence on heterosexual relations of children, *Feb.*, 139, 140, 142
permissiveness, delinquency due to, *Feb.*, 103
Patella. See also *Knee.*
dislocation, *Feb.*, 167
treatment, *Feb.*, 168
Patient-physician relationship, need for authority in, *Feb.*, 6
Pauling-Pressmann-Haurowitz theory of immunity, *May*, 278
Pediatrician, as specialist, *Feb.*, 222
delinquency and, *Feb.*, 113
learning problems and, *Feb.*, 127, 128
Peer problem in adolescence, *Feb.*, 135–7
Pelvis, pain in, *Feb.*, 50
Perception, body image, environment and, *Feb.*, 86
in mental retardation, *Feb.*, 157
Periarteritis nodosa vs. rheumatoid disease, *May*, 449, 450, 451
Peritoneum, lavage, in drug intoxications, *May*, 252
Permissiveness, parental, delinquency due to, *Feb.*, 103
Pertussis. See *Whooping cough.*
Pessary, stem, in dysmenorrhea, *Feb.*, 48
Pharyngitis, adenovirus, *May*, 299–300
Pharyngoconjunctival fever, *May*, 299–300
Phenergan. See *Promethazine.*
Phenobarbital in dysmenorrhea, *Feb.*, 47
Phenothiazine, derivatives, dosage, *May*, 265
side reactions, *May*, 259–62
intoxication, *May*, 249–50
Phenylbutazone in rheumatoid disease, *May*, 453
Phenylketonuria, *May*, 335
Phosphatase, alkaline, in plasma, *Feb.*, 21
Phosphate in iron intoxication, *May*, 248
Phosphoethanolamine excretion in urine, *May*, 336
Phosphorus, inorganic, in serum, *Feb.*, 20
Physical appearance, mental retardation and, *Feb.*, 153
Physical fitness, *Feb.*, 175–6, 182
Physician-patient relationship, need for authority in, *Feb.*, 6
Physiology of renal amino acid excretion, *May*, 336–8
Placenta, transmission of immunity or antibody across, *May*, 288
Plasma. See under *Blood.*
Plasma cell pneumonia. See *Pneumonia, interstitial.*
Plasmacytes in bone marrow in agammaglobulinemia, *May*, 413
Pneumocystis carinii. See *Pneumonia, interstitial.*
Pneumonia, advenovirus, *May*, 301–302
in barbiturate intoxication, *May*, 244
interstitial, in agammaglobulinemia, *May*, 424–5
plasma cell. See *Pneumonia, interstitial.*
Poliomyelitis, immunization, *May*, 289
psychologic effects, *Feb.*, 183, 184
Potassium, in digitalis intoxication, *May*, 249
in salicylate intoxication, *May*, 242
Practitioner, adolescent and, *Feb.*, **3–14**
Pregnancy, *Feb.*, 53
Prejudice, social, in mental retardation, *Feb.*, 160
Premarin. See under *Estrogens.*
Procaine amide in digitalis intoxication, *May*, 249
Procaine anesthesia in renal biopsy, *May*, 355
Prochlorperazine, side reactions, *May*, 260
Proctoscopy in ulcerative colitis, *Feb.*, 198

Progesterone in metrorrhagia, *Feb.*, 49, 50
Promethazine, side reactions, *May*, 260
Pronestyl. See *Procaine amide*.
Properdin concentration in agammaglobulinemia, *May*, 416–17
Protein, requirements, in adolescence, *Feb.*, 37–8
serum. See under *Blood, serum*.
Proteinuria, asymptomatic, renal biopsy in, *May*, 361–2
in galactosemia, *May*, 323
Pseudopolyposis as indication for operation in ulcerative colitis, *Feb.*, 200
Pseudotetanus in phenothiazine toxicity, *May*, 264
Psychiatry in mental retardation, *Feb.*, 160
Psychologic factors, in mental retardation, *Feb.*, 153–8
in ulcerative colitis, *Feb.*, 204, 205
Psychology, of adolescence, *Feb.*, **65–83**
developmental sequence, *Feb.*, 66, 67
of physical illness in adolescents, *Feb.*, **85–96**
Psychosomatic disorders in adolescence, *Feb.*, 96
Psychotherapy in ulcerative colitis, *Feb.*, 200, 201
Puberty. See also *Adolescence*.
cortisone-induced, *Feb.*, 24
Pulmonary. See *Lungs*.
Purpura, anaphylactoid, renal biopsy in, *May*, 364–6
vs. rheumatoid disease, *May*, 449, 450, 451
Pyelonephritis, renal biopsy in, *May*, 366–7

Q.T. Club, *Feb.*, 202

Race, delinquency and, *Feb.*, 112, 113
Rash in rheumatoid disease, *May*, 441
Rauwolfia derivatives, side reactions, *May*, 258–9
Reaction, antitoxin, to diphtheria toxoid, *May*, 284
antigen-antibody, *May*, 270
immune, to diphtheria toxoid, effect of passively transferred antibody on, *May*, 288
side, from tranquilizing drugs, *May*, **257–67**
skin, to streptococcal nucleoprotein, *May*, 272
Reaction, tuberculin, after BCG vaccination, *May*, 271
Reagin, *May*, 277
Reality, conflict with ego, in adolescents, *Feb.*, 71, 72
Rebellion in adolescence, *Feb.*, 102
Rejection, delinquency due to, *Feb.*, 105
Religion, adolescents' attitude towards, *Feb.*, 73
Renal. See also *Kidneys*.
amino-aciduria. See under *Amino-aciduria*.
Respiratory disease, acute, *May*, 299
Respiratory syncytial virus. See *CCA virus*.
Respiratory tract, infections, rheumatoid disease due to, *May*, 437
upper, viruses newly isolated from, *May*, **295–314**
Rest, bed, undesirable effects, *Feb.*, 183
Retardation, mental. See *Mental Retardation*.
Rheumatic fever vs. rheumatoid disease, *May*, 448 ff.
Rheumatoid disease, in agammaglobulinemia, *May*, 418–22
juvenile, *May*, **435–56**
acute-phase substances, *May*, 444–5
adult type, *May*, 439
clinical manifestations, *May*, 439–43
course, *May*, 451–2
diagnosis, *May*, 447
differential diagnosis, *May*, 447–51
etiology, *May*, 436–8
heredity in, *May*, 438
infantile type, *May*, 439
intermediate type, *May*, 439
laboratory features, *May*, 443–6
onset, *May*, 439–40
prognosis, *May*, 451–2
treatment, *May*, 452–4
RI-67 virus. See *Adenoviruses*.
Rickets, vitamin D-resistant, vs. renal amino-aciduria, *May*, 346
Roentgen examination, in rheumatoid disease, *May*, 446
of nasopharynx in agammaglobulinemia, *May*, 403, 404
RS virus. See *CCA virus*.

Salicylates, in rheumatoid disease, *May*, 453
intoxication, *May*, 238–42
Saline solution in salicylate intoxication, *May*, 241

Salpingitis, *Feb.*, 53
Scaphoid, accessory, *Feb.*, 169, 170
carpal, fracture of, *Feb.*, 166
Scheurmann's disease, *Feb.*, 170
Schick test in agammaglobulinemia, *May*, 402
Schlatter-Osgood disease, *Feb.*, 171, 181
Schoenlein-Henoch purpura. See *Purpura, anaphylactoid.*
School, as source of anxiety, *Feb.*, 195
failure in, *Feb.*, 117
anxiety as cause of, *Feb.*, 121
emotional problems as cause of, *Feb.*, 118, 119
sexual inhibition as cause of, *Feb.*, 120
social class as cause of, *Feb.*, 126, 127
superintellectualization as cause of, Feb., 119
teachers as cause of, *Feb.*, 122, 123
mental retardation and, *Feb.*, 159
readiness for, *Feb.*, 125
readiness to leave, *Feb.*, 125, 126
role of adolescents in, *Feb.*, 69
Scleroderma vs. rheumatoid disease, *May*, 449, 450
Scoliosis, idiopathic, *Feb.*, 169
Season, rheumatoid disease and, *May*, 437
Sedatives, *May*, 257, 258
intoxication due to, *May*, 242–5
Self-assertion, need for, in adolescents, *Feb.*, 71
Self-esteem, lack of, in mental retardation, *Feb.*, 156
Sendai virus. See *Para-influenza virus 1.*
Sensation-hunger, delinquency due to, *Feb.*, 98 ff.
Sensitivity, physiologic, to drugs, *May*, 236–7
Separation anxiety in ulcerative colitis, *Feb.*, 205
Serum. See under *Blood.*
Sex, adolescent and, *Feb.*, 193, 194
behavior, in mental retardation, *Feb.*, 155
characteristics, secondary, *Feb.*, 33
delinquency due to, *Feb.*, 143
development, delayed, *Feb.*, 28
effect on mental retardation, *Feb.*, 151, 152
heterosexual relations of adolescents, *Feb.*, 139–41, 142
identity, development of, *Feb.*, 67
inhibition, school failure due to, *Feb.*, 120
role, of adolescents, *Feb.*, 68
stimulation in illness, *Feb.*, 87
Skeleton. See *Bones.*
Skin, grafts, homotransplantation, in agammaglobulinemia, *May*, 417–18
rash, in rheumatoid disease, *May*, 441
response to streptococcal nucleoprotein, *May*, 272
Skin-sensitizing cell products, *May*, 277–8
Smallpox, immunization, *May*, 289
Social behavior, *Feb.*, 132
Social class, conflict, delinquency due to, *Feb.*, 143
school failure due to, *Feb.*, 126, 127
Social prejudice in mental retardation, *Feb.*, 160
Social system, definition, *Feb.*, 132
learning and, *Feb.*, 133
Sociologic factors in mental retardation, *Feb.*, 159
Sociology, elementary principles, *Feb.*, 132–4
of adolescence, *Feb.*, 131–45
Sodium bicarbonate, in iron intoxication, *May*, 248
in salicylate intoxication, May, 242
Sodium ethylenediamine tetra-acetic acid in digitalis intoxication, *May*, 249
Sodium lactate solution in salicylate intoxication, *May*, 241
Sodium phosphate in iron intoxication, May, 248
Somatotropin, *Feb.*, 16
Spasms, infantile, *May*, **373–80**
etiology, *May*, 375–6
pathology, *May*, 376
treatment, *May*, 377–9
Spine. See also *Back.*
abnormalities, congenital, *Feb.*, 169
curvature, kyphosis, *Feb.*, 170
scoliosis, idiopathic, *Feb.*, 169
epiphysitis, *Feb.*, 170
Sprain, of ankle, *Feb.*, 166
Osgood-Schlatter, *Feb.*, 171
Spondylolisthesis, *Feb.*, 169
Stem pessary in dysmenorrhea, *Feb.*, 48
Steroids, corticosteroids, excretion of, *Feb.*, 23
in rheumatoid disease, *May*, 453, 454
in ulcerative colitis, *Feb.*, 200
Stilbestrol in dysmenorrhea, *Feb.*, 48
Still's disease, *May*, 436. See also *Rheumatoid disease, juvenile.*
Stimulation, overstimulation, juvenile delinquency due to, *Feb.*, 98–101
Stomach, lavage, in drug intoxications, *May*, 251
Stone bruise of heel, *Feb.*, 170, 171
Streptococcal nucleoprotein, skin reaction to, *May*, 272

Streptodornase, hypersensitivity to, in agammaglobulinemia, *May*, 422
Streptokinase, hypersensitivity to, in agammaglobulinemia, *May*, 422
Success, need for, in adolescents, *Feb.*, 71
Superintellectualization, school failure due to, *Feb.*, 119
Surgery, effect on adolescents, *Feb.*, 95
in ulcerative colitis, *Feb.*, 201, 202
plastic, in adolescents, *Feb.*, 94
Syndrome, effort, *Feb.*, 176
Synovial fluid in rheumatoid disease, *May*, 446
Syrup of ipecac to induce emesis, *May*, 251

TEACHERS, school failure due to, *Feb.*, 122, 123
Test, Schick, in agammaglobulinemia, *May*, 402
zinc turbidity, in agammaglobulinemia, *May*, 402
Testes, undescended, adolescent's concern about, *Feb.*, 193
Testosterone propionate in dysmenorrhea, *Feb.*, 48
Tetanus, immunization, *May*, 289
vs. phenothiazine toxicity, *May*, 264
Tetracycline in agammaglobulinemia, *May*, 428
Thorazine. See *Chlorpromazine*.
Thrill-seeking activity vs. delinquency, *Feb.*, 99, 100
Thyroid extract in dysmenorrhea, *Feb.*, 47, 48, 61, 62
Thyroid-stimulating hormone, *Feb.*, 15
Toxoid, diphtheria, antitoxin reaction to, *May*, 284
immune response to, effect of passively transferred antibody on, *May*, 288
Training in athletics, *Feb.*, 174, 175, 176
Tranquilizers, intoxication due to, *May*, 249–50
side reactions from, *May*, **257–67**
toxicity, symptoms, *May*, 262–4
Transferase, galactose-1-phosphate uridyl, values of, *May*, 318
Transferase, glucuronyl. See *Glucuronyl transferase*.
Transferase system, glucuronyl, in newborn, *May*, 381–96
Transfusion. See under *Blood*.
Trauma, in athletics, *Feb.*, 165–8
rheumatoid disease due to, *May*, 437
TSH. See *Thyroid-stimulating hormone*.
Tuberculin reaction after BCG vaccination, *May*, 271
Tuberculosis, reactions to, in agammaglobulinemia, *May*, 422–3
Tumor, ovarian, *Feb.*, 55
Typhoid, immunization, *May*, 291

UDPGA. See *Uridine diphosphate glucuronic acid*.
Ulcerative colitis, *Feb.*, **197–206**
Uridine diphosphate glucose dehydrogenase, *May*, 383–4
Uridine diphosphate glucuronic acid, *May*, 383
Urine, corticosteroids in, *Feb.*, 23
estrogens in, *Feb.*, 17, 18, 19
in galactosemia, *May*, 323–4
17-ketosteroids in, *Feb.*, 19
maple syrup urine disease, *May*, 335
phosphoethanolamine in, *May*, 336
Uterus, cervix, dilatation of, in dysmenorrhea, *Feb.*, 48
size, determination of, *Feb.*, 49

VACCINATION, BCG, tuberculin reaction after, *May*, 271
Vaccine, adenovirus, *May*, 303
four-component, *May*, 290
Vagina, discharge from, *Feb.*, 51–2
Value scales of adolescents, *Feb.*, 70
Values, adolescents' need for, *Feb.*, 79
home, vs. community values, *Feb.*, 112
Versenate. See *Edathamil*.
Viruses, 2060, *May*, 308–309
adenoviruses, *May*, 296–303
Coe, *May*, 309–310
infections, in agammaglobulinemia, *May*, 408–10
JH, *May*, 308–309
myxoviruses, *May*, 303–308
newly isolated from upper respiratory tract, *May*, **295–314**
Vitamin D requirements in adolescence, *Feb.*, 38–40
Vomiting in drug intoxications, *May*, 251

WHOOPING cough, immunization, *May*, 289

X-RAY. See *Roentgen*.

ZINC turbidity test in agammaglobulinemia, *May*, 402